<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cytoa24510" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cytometry A</journal-id><journal-id journal-id-type="iso-abbrev">Cytometry A</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">CYTO</journal-id><journal-title-group><journal-title>Cytometry</journal-title></journal-title-group><issn pub-type="ppub">1552-4922</issn><issn pub-type="epub">1552-4930</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9298022</article-id><article-id pub-id-type="pmcid-ver">PMC9298022.1</article-id><article-id pub-id-type="pmcaid">9298022</article-id><article-id pub-id-type="pmcaiid">9298022</article-id><article-id pub-id-type="pmid">34693626</article-id><article-id pub-id-type="doi">10.1002/cyto.a.24510</article-id><article-id pub-id-type="publisher-id">CYTOA24510</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Omip</subject></subj-group><subj-group subj-group-type="heading"><subject>Omip</subject></subj-group></article-categories><title-group><article-title>
<styled-content style="fixed-case" toggle="no">OMIP&#8208;080: 29&#8208;Color</styled-content> flow cytometry panel for comprehensive evaluation of <styled-content style="fixed-case" toggle="no">NK</styled-content> and T cells reconstitution after hematopoietic stem cells transplantation</article-title><alt-title alt-title-type="left-running-head">Vanikova et al.</alt-title></title-group><contrib-group><contrib id="cytoa24510-cr-0001" contrib-type="author"><name name-style="western"><surname>Vanikova</surname><given-names initials="S">Sarka</given-names></name><xref rid="cytoa24510-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cytoa24510-cr-0002" contrib-type="author"><name name-style="western"><surname>Koladiya</surname><given-names initials="A">Abhishek</given-names></name><xref rid="cytoa24510-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cytoa24510-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Musil</surname><given-names initials="J">Jan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9378-5956</contrib-id><xref rid="cytoa24510-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>jan.musil@uhkt.cz</email></address></contrib></contrib-group><aff id="cytoa24510-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Immunomonitoring and Flow Cytometry</named-content>
<institution>Institute of Hematology and Blood Transfusion</institution>
<city>Prague</city>
<country country="CZ">Czech Republic</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Jan Musil, Department of Immunomonitoring and Flow Cytometry, Institute of Hematology and Blood Transfusion, U Nemocnice 2094/1, 128 00 Prague, Czech Republic.<break/>
Email: <email>jan.musil@uhkt.cz</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2022</year></pub-date><volume>101</volume><issue seq="100">1</issue><issue-id pub-id-type="pmc-issue-id">412791</issue-id><issue-id pub-id-type="doi">10.1002/cyto.a.v101.1</issue-id><fpage>21</fpage><lpage>26</lpage><history><date date-type="rev-recd"><day>22</day><month>9</month><year>2021</year></date><date date-type="received"><day>12</day><month>3</month><year>2021</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>07</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>21</day><month>07</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-07-29 10:19:40.070"><day>29</day><month>07</month><year>2022</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2021 The Authors. <italic toggle="yes">Cytometry Part A</italic> published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CYTO-101-21.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CYTO-101-21.pdf"/><abstract><title>Abstract</title><p>This 29&#8208;color panel was developed and optimized for the monitoring of NK cell and T cell reconstitution in peripheral blood of patients after HSCT. We considered major post&#8208;HSCT complications during the design, such as relapses, viral infections, and GvHD and identification of lymphocyte populations relevant to their resolution. The panel includes markers for all major NK cell and T cell subsets and analysis of their development and qualitative properties. In the NK cell compartment, we focus mainly on CD57&#8201;+&#8201;NKG2C+ cells and the expression of activating (NKG2D, DNAM&#8208;1) and inhibitory receptors (NKG2A, TIGIT). Another priority is the characterization of T cell reconstitution; therefore, we included detection of CD4+ RTEs based on CD45RA, CD62L, CD95, and CD31 as a marker of thymus function. Besides that, we also analyze the emergence and properties of major T cell populations with a particular interest in CD8, Th1, ThCTL, and Treg subsets. Overall, the panel allows for comprehensive analysis of the reconstituting immune system and identification of potential markers of immune cell dysfunction.</p></abstract><funding-group><award-group id="funding-0001"><funding-source>European Regional Development Fund and the state budget of the Czech Republic, project AIIHHP</funding-source><award-id>CZ.02.1.01/0.0/0.0/16_025/0007428 OP RDE MEYS</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Ministerstvo Zdravotnictv&#237; Cesk&#233; Republiky
</institution><institution-id institution-id-type="doi">10.13039/501100003243</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source>H CZ &#8208; DRO (Institute of Hematology and Blood Tranfusion &#8208; IHBT)</funding-source><award-id>IN 00023736</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="6"/><word-count count="4643"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2022</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:20.07.2022</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cytoa24510-cit-9001"><string-name name-style="western"><surname>Vanikova</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Koladiya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Musil</surname><given-names>J</given-names></string-name>. <article-title>
<styled-content style="fixed-case" toggle="no">OMIP&#8208;080: 29&#8208;Color</styled-content> flow cytometry panel for comprehensive evaluation of <styled-content style="fixed-case" toggle="no">NK</styled-content> and T cells reconstitution after hematopoietic stem cells transplantation</article-title>. <source>Cytometry</source>. <year>2022</year>;<volume>101</volume>:<fpage>21</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1002/cyto.a.24510</pub-id><pub-id pub-id-type="pmid">34693626</pub-id><pub-id pub-id-type="pmcid">PMC9298022</pub-id></mixed-citation>
</p><fn-group id="cytoa24510-ntgp-0001"><fn id="cytoa24510-note-0001" fn-type="equal"><p>Sarka Vanikova and Abhishek Koladiya contributed equally to this work.</p></fn><fn id="cytoa24510-note-1002"><p>
<bold>Funding information</bold> European Regional Development Fund and the state budget of the Czech Republic, project AIIHHP, Grant/Award Number: CZ.02.1.01/0.0/0.0/16_025/0007428 OP RDE MEYS; Ministerstvo Zdravotnictv&#237; Cesk&#233; Republiky; H CZ &#8208; DRO (Institute of Hematology and Blood Tranfusion &#8208; IHBT), Grant/Award Number: IN 00023736</p></fn></fn-group></notes></front><body id="cytoa24510-body-0001"><sec sec-type="background" id="cytoa24510-sec-0001"><label>1</label><title>BACKGROUND</title><p>Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment available to patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [<xref rid="cytoa24510-bib-0001" ref-type="bibr">1</xref>, <xref rid="cytoa24510-bib-0002" ref-type="bibr">2</xref>]. Furthermore, it is indicated as a treatment for other malignant and non&#8208;malignant diseases [<xref rid="cytoa24510-bib-0003" ref-type="bibr">3</xref>, <xref rid="cytoa24510-bib-0004" ref-type="bibr">4</xref>, <xref rid="cytoa24510-bib-0005" ref-type="bibr">5</xref>]. Although HSCT represents the most effective immunotherapy to date, it is associated with severe post&#8208;transplant complications that are the result of improper immune system function. These include relapse of the original disease, graft&#8208;versus&#8208;host&#8208;disease (GvHD) and infectious complications, such as reactivation of latent human cytomegalovirus (HCMV) infection [<xref rid="cytoa24510-bib-0006" ref-type="bibr">6</xref>]. Therefore, monitoring markers of immune system dysfunction is highly sought as it opens up the possibility for early therapeutic intervention. For example, the transfer of virus&#8208;specific T cells is actively investigated in clinical trials for the treatment of viral complications [<xref rid="cytoa24510-bib-0007" ref-type="bibr">7</xref>].</p><p>Flow cytometry represents the method of choice when evaluating the status of the post&#8208;transplant immune system as it can identify quantitative and qualitative differences between the regenerating and healthy immune system (Table&#160;<xref rid="cytoa24510-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="cytoa24510-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Summary table for application of OMIP&#8208;080</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Purpose</td><td align="left" valign="top" rowspan="1" colspan="1">T cells and NK cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Species</td><td align="left" valign="top" rowspan="1" colspan="1">Human</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cell types</td><td align="left" valign="top" rowspan="1" colspan="1">PBMC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cross&#8208;reference</td><td align="left" valign="top" rowspan="1" colspan="1">OMIP&#8208;004,007,013,015,017,024,030,036,037,039,042,050,058,060</td></tr></tbody></table></table-wrap><p>Therefore, we have developed a 29&#8208;color panel to monitor the reconstitution of NK (natural killer) cell and T cell subpopulations as they are the major drivers of anti&#8208;leukemia and anti&#8208;pathogen responses as well as gatekeepers of tissue tolerance.</p><p>NK cells represent the first lymphocyte population to recover after HSCT and play an essential role in controlling viral infections and mediating the graft&#8208;versus&#8208;leukemia (GvL) effect [<xref rid="cytoa24510-bib-0008" ref-type="bibr">8</xref>, <xref rid="cytoa24510-bib-0009" ref-type="bibr">9</xref>, <xref rid="cytoa24510-bib-0010" ref-type="bibr">10</xref>].</p><p>However, their function, that is, cytotoxicity and cytokine production, is heavily impaired, and it can take up to 6&#160;months until full functionality is restored [<xref rid="cytoa24510-bib-0011" ref-type="bibr">11</xref>, <xref rid="cytoa24510-bib-0012" ref-type="bibr">12</xref>]. To be able to comprehensively monitor the reconstitution of the NK cell compartment, we have included several types of maturation, functional and qualitative markers (Table&#160;<xref rid="cytoa24510-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="cytoa24510-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Reagents used for OMIP&#8208;080</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Antigen</th><th align="left" valign="bottom" rowspan="1" colspan="1">Fluorochrome</th><th align="left" valign="bottom" rowspan="1" colspan="1">Clone</th><th align="left" valign="bottom" rowspan="1" colspan="1">Purpose</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">CD62L</td><td align="left" valign="top" rowspan="1" colspan="1">BUV395</td><td align="left" valign="top" rowspan="1" colspan="1">DREG&#8208;56</td><td align="left" valign="top" rowspan="1" colspan="1">T cell differentiation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">Viability</td><td align="left" valign="top" rowspan="1" colspan="1">Live&#8208;Dead Blue</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">Viability</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">CD69</td><td align="left" valign="top" rowspan="1" colspan="1">BUV496</td><td align="left" valign="top" rowspan="1" colspan="1">FN50</td><td align="left" valign="top" rowspan="1" colspan="1">NK and T cell activation marker</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">CCR6 (CD196)</td><td align="left" valign="top" rowspan="1" colspan="1">BUV563</td><td align="left" valign="top" rowspan="1" colspan="1">11A9</td><td align="left" valign="top" rowspan="1" colspan="1">Chemokine receptor; Th subset identification</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">CD27</td><td align="left" valign="top" rowspan="1" colspan="1">BUV615</td><td align="left" valign="top" rowspan="1" colspan="1">M&#8208;T271</td><td align="left" valign="top" rowspan="1" colspan="1">T cell differentiation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">PD1 (CD279)</td><td align="left" valign="top" rowspan="1" colspan="1">BUV661</td><td align="left" valign="top" rowspan="1" colspan="1">EH12.1</td><td align="left" valign="top" rowspan="1" colspan="1">T cell inhibitory receptor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">CD25</td><td align="left" valign="top" rowspan="1" colspan="1">BUV737</td><td align="left" valign="top" rowspan="1" colspan="1">2A3</td><td align="left" valign="top" rowspan="1" colspan="1">T cell activation; Treg identification</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">CD8</td><td align="left" valign="top" rowspan="1" colspan="1">BUV805</td><td align="left" valign="top" rowspan="1" colspan="1">RPA&#8208;T8</td><td align="left" valign="top" rowspan="1" colspan="1">CD8 T cell and NKT&#8208;like cell lineage marker</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">NKG2A (CD159a)</td><td align="left" valign="top" rowspan="1" colspan="1">BV421</td><td align="left" valign="top" rowspan="1" colspan="1">131411</td><td align="left" valign="top" rowspan="1" colspan="1">NK and NKT&#8208;like cell inhibitory receptor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">CD45RA</td><td align="left" valign="top" rowspan="1" colspan="1">PB</td><td align="left" valign="top" rowspan="1" colspan="1">HI100</td><td align="left" valign="top" rowspan="1" colspan="1">T cell differentiation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">Tim3</td><td align="left" valign="top" rowspan="1" colspan="1">BV480</td><td align="left" valign="top" rowspan="1" colspan="1">7D3</td><td align="left" valign="top" rowspan="1" colspan="1">T cell inhibitory receptor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">CD4</td><td align="left" valign="top" rowspan="1" colspan="1">BV570</td><td align="left" valign="top" rowspan="1" colspan="1">RPA&#8208;T4</td><td align="left" valign="top" rowspan="1" colspan="1">CD4 T cell lineage marker</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">CD57</td><td align="left" valign="top" rowspan="1" colspan="1">BV605</td><td align="left" valign="top" rowspan="1" colspan="1">QA17A04</td><td align="left" valign="top" rowspan="1" colspan="1">T cell and NK cell differentiation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">CD95</td><td align="left" valign="top" rowspan="1" colspan="1">BV650</td><td align="left" valign="top" rowspan="1" colspan="1">DX2</td><td align="left" valign="top" rowspan="1" colspan="1">T cell activation and differentiation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">&#947;&#948;TCR</td><td align="left" valign="top" rowspan="1" colspan="1">BV711</td><td align="left" valign="top" rowspan="1" colspan="1">11F2</td><td align="left" valign="top" rowspan="1" colspan="1">&#947;&#948; T cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">DNAM&#8208;1 (CD226)</td><td align="left" valign="top" rowspan="1" colspan="1">BV750</td><td align="left" valign="top" rowspan="1" colspan="1">DX11</td><td align="left" valign="top" rowspan="1" colspan="1">T cell and NK cell activating receptor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">CD31</td><td align="left" valign="top" rowspan="1" colspan="1">BV786</td><td align="left" valign="top" rowspan="1" colspan="1">WM59</td><td align="left" valign="top" rowspan="1" colspan="1">Adhesion molecule; identification of RTE</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="left" valign="top" rowspan="1" colspan="1">CCR10</td><td align="left" valign="top" rowspan="1" colspan="1">BB515</td><td align="left" valign="top" rowspan="1" colspan="1">1B5</td><td align="left" valign="top" rowspan="1" colspan="1">Chemokine receptor; Th subset identification</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">CCR4 (CD194)</td><td align="left" valign="top" rowspan="1" colspan="1">BB700</td><td align="left" valign="top" rowspan="1" colspan="1">1G1</td><td align="left" valign="top" rowspan="1" colspan="1">Chemokine receptor; Th subset identification</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">TIGIT</td><td align="left" valign="top" rowspan="1" colspan="1">BB750</td><td align="left" valign="top" rowspan="1" colspan="1">741182</td><td align="left" valign="top" rowspan="1" colspan="1">T cell and NK cell inhibitory receptor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">NKG2D (CD314)</td><td align="left" valign="top" rowspan="1" colspan="1">BB790</td><td align="left" valign="top" rowspan="1" colspan="1">1D11</td><td align="left" valign="top" rowspan="1" colspan="1">NK cell activating receptor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">NKG2C (CD159c)</td><td align="left" valign="top" rowspan="1" colspan="1">PE</td><td align="left" valign="top" rowspan="1" colspan="1">FAB138P</td><td align="left" valign="top" rowspan="1" colspan="1">NK cell activating receptor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">CD56</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;CF594</td><td align="left" valign="top" rowspan="1" colspan="1">NCAM16.2</td><td align="left" valign="top" rowspan="1" colspan="1">NK cell and NKT&#8208;like cell lineage marker</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">CXCR3 (CD183)</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy5</td><td align="left" valign="top" rowspan="1" colspan="1">1C6/CXCR3</td><td align="left" valign="top" rowspan="1" colspan="1">Chemokine receptor; Th subset identification</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">25</td><td align="left" valign="top" rowspan="1" colspan="1">FoxP3</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy5.5</td><td align="left" valign="top" rowspan="1" colspan="1">PCH101</td><td align="left" valign="top" rowspan="1" colspan="1">Master transcription factor for Tregs</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">26</td><td align="left" valign="top" rowspan="1" colspan="1">CD39</td><td align="left" valign="top" rowspan="1" colspan="1">PE&#8208;Cy7</td><td align="left" valign="top" rowspan="1" colspan="1">A1</td><td align="left" valign="top" rowspan="1" colspan="1">Treg activation marker</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">27</td><td align="left" valign="top" rowspan="1" colspan="1">CD3</td><td align="left" valign="top" rowspan="1" colspan="1">AF647</td><td align="left" valign="top" rowspan="1" colspan="1">UCHT1</td><td align="left" valign="top" rowspan="1" colspan="1">T cell and NKT&#8208;like cell lineage marker</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">28</td><td align="left" valign="top" rowspan="1" colspan="1">CD16</td><td align="left" valign="top" rowspan="1" colspan="1">AF700</td><td align="left" valign="top" rowspan="1" colspan="1">3G8</td><td align="left" valign="top" rowspan="1" colspan="1">NK cell differentiation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">29</td><td align="left" valign="top" rowspan="1" colspan="1">Perforin</td><td align="left" valign="top" rowspan="1" colspan="1">APC Fire750</td><td align="left" valign="top" rowspan="1" colspan="1">B&#8208;D48</td><td align="left" valign="top" rowspan="1" colspan="1">Cytolytic function</td></tr></tbody></table><table-wrap-foot id="cytoa24510-ntgp-0002"><fn id="cytoa24510-note-0002"><p>Abbreviations: AF, Alexa Fluor; APC, Allophycocyanin; BB, Brilliant Blue; BUV, Brilliant Ultraviolet; BV, Brilliant Violet; Cy, cyanine; PB, Pacific blue; PE, R&#8208;phycoerythrin.</p></fn></table-wrap-foot></table-wrap><p>Maturation of the NK cell compartment is monitored based on the identification of the four major subsets. These include CD56hiCD16&#8722; cells representing producers of cytokines such as interferon&#8208;gamma (IFN&#947;) and tumor necrosis factor alpha (TNF&#945;) [<xref rid="cytoa24510-bib-0013" ref-type="bibr">13</xref>], CD56loCD16+ highly differentiated cytotoxic cells, CD56hiCD16+ cells representing a transitional phenotype sharing functional characteristics with CD56hiCD16&#8722; and CD56loCD16+ such as cytotoxicity and cytokine production, and CD56loCD16&#8722; which is a heterogeneous population composed of activated NK cells that downregulate CD16 and potential precursors of the CD56loCD16+ subset [<xref rid="cytoa24510-bib-0014" ref-type="bibr">14</xref>, <xref rid="cytoa24510-bib-0015" ref-type="bibr">15</xref>].</p><p>HSCT does not only affect the distribution of NK cell subsets but has also been shown to affect their functional properties, such as the production of perforin and IFN&#947; [<xref rid="cytoa24510-bib-0016" ref-type="bibr">16</xref>]. Therefore, we have included perforin and Tim3 as a proposed regulator of IFN&#947; production in NK cells [<xref rid="cytoa24510-bib-0012" ref-type="bibr">12</xref>]. Furthermore, regarding relapse of the original disease expression of activating receptors NKG2D and DNAM&#8208;1 and inhibitory receptors, NKG2A and TIGIT are monitored due to their role in leukemia immune escape [<xref rid="cytoa24510-bib-0017" ref-type="bibr">17</xref>, <xref rid="cytoa24510-bib-0018" ref-type="bibr">18</xref>, <xref rid="cytoa24510-bib-0019" ref-type="bibr">19</xref>].</p><p>T cells represent the orchestrators of adaptive immunity and are indispensable for long&#8208;lasting protective immune responses. In comparison to NK cells, their reconstitution is more complex as it is highly influenced by the type of graft, that is, umbilical cord blood, bone marrow, mobilized blood stem cells [<xref rid="cytoa24510-bib-0020" ref-type="bibr">20</xref>]. Two pathways of reconstitution exist, namely homeostatic expansion and de novo differentiation via the thymus [<xref rid="cytoa24510-bib-0011" ref-type="bibr">11</xref>].</p><p>In this panel, we define two main subsets of T cells based on the type of T cell receptor (TCR), namely &#947;&#948;TCR+ cells and &#947;&#948;TCR&#8722;, which we consider to be &#945;&#946; T cells. We further subtype &#945;&#946; T cells based on CD56 expression into CD56+ T cells and classical T cells (Figure&#160;<xref rid="cytoa24510-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="cytoa24510-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Manual gating strategy and algorithmic analysis. (<bold>A</bold>) Before the identification of individual subsets, debris, doublets and dead cells were removed. (<bold>B</bold>) Cell lineages were identified based on the expression of the following phenotypes: CD56+ (NK cells), CD56&#8722;CD3+&#8201;&#947;&#948;TCR+ (&#947;&#948;T cells), CD3+&#947;&#948;TCR&#8208;CD56+ T cells, CD3+&#947;&#948;TCR&#8722;CD56&#8722;CD4+ (T helper cells) and CD3+&#947;&#948;TCR&#8722;CD56&#8722;CD8+ (T cytotoxic cells). (<bold>C</bold>) CD4+ T cells were delineated into CD25+FoxP3+ Tregs and non&#8208;Treg cells. Activation of Tregs was evaluated based on the expression of CD39. Furthermore, expression of PD1, TIGIT, and Tim3 identifying highly suppressive Tregs was evaluated. Cells in the non&#8208;Treg gate were divided into individual T helper subsets based on the combination of chemokine receptors. These cells were first gated for perforin+CD27&#8722;CTL cells and perforin&#8722; cells. The perforin&#8722; cells were gated for CCR10+&#8201;CCR4+&#8201;CCR6+ Th22 cells, CCR10+&#8201;CCR4+CCR6&#8722; ThGM&#8208;CSF, CCR10&#8722;CCR4+CCR6&#8722; Th2 cells, CCR10&#8722;CCR4+CCR6+ Th17 cells, CCR10&#8208;CCR4&#8208;CCR6+CXCR3&#8722; Th9 cells and CCR10&#8722;CCR4&#8722;CCR6+/&#8722;CXCR3+ Th1 cells. Thymic function was evaluated on CD4+ gated cell via identification of CD45RA+CD62L+CD95&#8722;CD31+ cells. (<bold>D</bold>) Gated CD8+ cells were subtyped into individual memory subsets based on CD45RA and CD62L and expression of inhibitory receptors, activation markers and perforin was evaluated. Inhibiting receptors are only weakly expressed on T cells from healthy donors, and therefore we show a comparison between healthy and patients after HSCT. (<bold>E</bold>) Gating of &#947;&#948;T cells based on CD57&#8722;NKG2A+ cytokine&#8208;producing cells, CD57+NKG2A&#8722; terminally differentiated cytotoxic cells and CD57&#8722;NKG2A&#8722; with intermediate phenotype. Expression of perforin and TIGIT on these cells is depicted using a histogram. (<bold>F</bold>) NK cells were subtyped based on the expression of CD56 and CD16, and a comparison of a healthy donor and post&#8208;HSCT patient is shown. CD56hiCD16&#8208; cells represent less differentiated cytokine&#8208;producing cells characterized by low expression perforin and high expression of CD27, whereas CD56loCD16+ cells express high levels of perforin and lack NKG2A and CD27. These cells include a subset of CD57+NKG2C+ memory&#8208;like NK cells. (<bold>G</bold>) CD56+ T cells can be divided into three main lineages based on CD4 and CD8. The CD4+ cells are enriched with cytotoxic perforin expressing cells mostly terminally differentiated, as evident by expression of CD57. The CD8+ cell can be split into two subsets based on the expression of NKG2C. These subsets show distinct differentiation status, as evident by the expression patterns of CD45RA and CD62L. (<bold>H</bold>) Identification of individual cell types was performed on gated live single cells using the Embedding Guided by Self&#8208;Organizing Map (EmbedSOM) algorithm&#160;[<xref rid="cytoa24510-bib-0020" ref-type="bibr">20</xref>]. Expression pattern of markers on individual cell subsets is show in <xref rid="cytoa24510-supitem-0001" ref-type="supplementary-material">Figure S8</xref>. FSC, forward&#8208;scatter; SSC, side&#8208;scatter [Color figure can be viewed at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://wileyonlinelibrary.com" ext-link-type="uri">wileyonlinelibrary.com</ext-link>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CYTO-101-21-g001.jpg"/></fig><p>&#947;&#948; T cells represent a bridge between innate and adaptive responses, they recognize infected or malignant cells either through the expression of activating receptors which they share with NK cells like NKG2D, NKG2C and DNAM&#8208;1 or by recognition through their TCR, that recognizes phosphoantigens including intermediates from the isoprenoid biosynthesis pathway [<xref rid="cytoa24510-bib-0021" ref-type="bibr">21</xref>, <xref rid="cytoa24510-bib-0022" ref-type="bibr">22</xref>]. In our panel, we subtype &#947;&#948; T cells based on the expression of CD57 and NKG2A into CD57&#8201;+&#8201;NKG2A&#8722; terminally differentiated highly cytotoxic cells, CD57&#8722;NKG2A&#8722; cytotoxic cells and cytokine&#8208;producing CD57&#8208;NKG2A+ cells. Furthermore, we are able to evaluate the expression of costimulatory molecules such as NKG2D, which mediates TCR unrestricted effector functions, and CD27 which has been proposed to co&#8208;stimulate and thereby boost recognition of target cells via TCR [<xref rid="cytoa24510-bib-0023" ref-type="bibr">23</xref>].</p><p>NKT&#8208;like cells represent another subset of T cells that share similarities with NK cells. In our panel, we define them as CD3&#8201;+&#8201;&#947;&#948;TCR&#8208;CD56+ cells. It has to be noted that this population is highly heterogeneous, and besides, NKT&#8208;like cells contain CD1d&#8208;restricted type I (iNKT) and type II NKT cells; however, these represent a minority [<xref rid="cytoa24510-bib-0024" ref-type="bibr">24</xref>]. Currently, it has been proposed that NKT&#8208;like cells arise from classical T&#8208;cells that start to express NK cell markers after prolonged antigen stimulation [<xref rid="cytoa24510-bib-0025" ref-type="bibr">25</xref>]. Their physiological role is currently under investigation. As there is no clear agreement about the nomenclature of these cells, we further refer to them as CD56+ T cells. In our panel, we identify three subsets of CD56+ T cells: CD4+, CD8+, and CD4&#8722; CD8&#8722; (DN) cells. We further subdivide the CD8 subset into NKG2C&#8722; and NKG2C+ cells as these might represent cells with specific roles for HCMV. These cells are dominated by the CD45RA+ CD62L&#8722; effector phenotype, are highly cytotoxic and lack expression of the NKG2A receptor. CD4+ CD56+ T cells are also highly differentiated with an effector memory phenotype. These cells contain a substantial population of cytotoxic cells, as evidenced by the expression of perforin and CD57.</p><p>Classical T cells are defined in our panel as CD3&#8201;+&#8201;CD56&#8201;&#8722;&#8201;&#947;&#948;TCR&#8722;, however it has to be noted that the population of CD3&#8201;+&#8201;CD56&#8201;&#8722;&#8201;&#947;&#948;TCR&#8722; is actually heterogeneous and includes true classical &#945;&#946;T cells and mucosal&#8208;associated invariant T (MAIT) cells characterized by the expression of an invariant &#945;&#946;TCR [<xref rid="cytoa24510-bib-0026" ref-type="bibr">26</xref>]. &#945;&#946;T cells are the centerpiece of adaptive immune responses. However, they are heavily affected by HSCT. The most prominent change, when compared to healthy, is the inverse ratio of CD4:CD8 T cells which is caused by faster regeneration of CD8+ T cells that reach normal levels in 100&#8201;days, whereas CD4+ T cell regeneration can take up to a year [<xref rid="cytoa24510-bib-0011" ref-type="bibr">11</xref>, <xref rid="cytoa24510-bib-0027" ref-type="bibr">27</xref>]. As mentioned above, reconstitution in the months after HSCT is driven by the homeostatic expansion of T cells contained in the graft. However, the only way of reconstituting a broad TCR repertoire that can efficiently protect against invading pathogens is through the thymus [<xref rid="cytoa24510-bib-0028" ref-type="bibr">28</xref>]. To monitor the thymic output, we use the measurement of recent thymic emigrants (RTE) in the na&#239;ve CD4 compartment based on the expression of CD31 [<xref rid="cytoa24510-bib-0029" ref-type="bibr">29</xref>]. CD8+ T cells reconstitute faster, but there is currently no validated marker for CD8+ RTEs; therefore, we monitor only the emergence of na&#239;ve CD8+ T cells defined as CD45RA&#8201;+&#8201;CD62L&#8201;+&#8201;CD95&#8722;.</p><p>As early post&#8208;transplant responses heavily rely on CD8+ T cells, we have included several types of markers for assessing the functional status of the CD8+ T cell compartment. First of all, we monitor the distribution of different memory subsets such as CD45RA&#8201;+&#8201;CD62L&#8201;+&#8201;CD95+ memory stem cells (Tscm), CD45RA&#8201;&#8722;&#8201;CD62L+ central memory cells (Tcm), CD45RA&#8201;&#8722;&#8201;CD62L&#8722; effector memory cells (Tem), and finally CD45RA&#8201;+&#8201;CD62L&#8722; effector cells (Teff). Besides that, we have also included activation markers such as the early activation marker CD69, CD25, and perforin as a marker for effector function.</p><p>Furthermore, we included markers of T cell exhaustion and senescence, that is, PD1, TIGIT, Tim3, and CD57, as these are important when considering AML relapse [<xref rid="cytoa24510-bib-0030" ref-type="bibr">30</xref>, <xref rid="cytoa24510-bib-0031" ref-type="bibr">31</xref>, <xref rid="cytoa24510-bib-0032" ref-type="bibr">32</xref>].</p><p>CD4+ T cells are the main regulators of innate and adaptive immune responses. We have designed our panel to separate the main T helper (Th) subsets, that is, CD25&#8201;+&#8201;FoxP3 regulatory T cells (Tregs), perforin+ CD27&#8722; Th cytotoxic lymphocytes (ThCTL), CCR10&#8208;CCR4&#8208;CXCR3+ Th1, CCR10&#8201;+&#8201;CCR4&#8201;+&#8201;CCR6+ Th22, CCR10&#8201;&#8722;&#8201;CCR4&#8201;+&#8201;CCR6+ Th17, CCR10&#8201;&#8722;&#8201;CCR4&#8201;+&#8201;CCR6&#8722; Th2, CCR10&#8201;+&#8201;CCR4&#8201;+&#8201;CCR6&#8722; Th granulocyte&#8208;macrophage colony&#8208;stimulating factor (ThGM&#8208;CSF), and finally CCR10&#8201;&#8722;&#8201;CCR4&#8201;&#8722;&#8201;CXCR3&#8201;&#8722;&#8201;CCR6+ Th9 cells.</p><p>Monitoring of Tregs in this panel is a priority as they have been shown to adversely affect anti&#8208;leukemic responses and can influence the occurrence of GvHD [<xref rid="cytoa24510-bib-0033" ref-type="bibr">33</xref>, <xref rid="cytoa24510-bib-0034" ref-type="bibr">34</xref>, <xref rid="cytoa24510-bib-0035" ref-type="bibr">35</xref>]. We monitor Th&#8208;like Treg phenotypes, as it has been proposed that Tregs mirror the effector cells they suppress [<xref rid="cytoa24510-bib-0036" ref-type="bibr">36</xref>]. Additionally, we included markers of highly suppressive Tregs, i.e., CD39, PD1, Tim3 and TIGIT [<xref rid="cytoa24510-bib-0037" ref-type="bibr">37</xref>, <xref rid="cytoa24510-bib-0038" ref-type="bibr">38</xref>].</p><p>Another priority of our panel is the identification of exhaustion markers on Th1 and ThCTL cells, as these represent important mediators of antiviral and anti&#8208;leukemic responses [<xref rid="cytoa24510-bib-0039" ref-type="bibr">39</xref>, <xref rid="cytoa24510-bib-0040" ref-type="bibr">40</xref>].</p><p>Other non&#8208;Treg subsets like Th17 and Th22 can play an important role in immunity against bacterial pathogens causing post&#8208;HSCT complications such as <italic toggle="yes">Pseudomonas aeruginosa, Streptococcus pneumonie or Pneumocystis jirovecii</italic> [<xref rid="cytoa24510-bib-0041" ref-type="bibr">41</xref>, <xref rid="cytoa24510-bib-0042" ref-type="bibr">42</xref>, <xref rid="cytoa24510-bib-0043" ref-type="bibr">43</xref>]. Finally, we utilized the EmbedSOM algorithm to identify important cell subsets from live single cells (Figure&#160;<xref rid="cytoa24510-fig-0001" ref-type="fig">1H</xref>). [<xref rid="cytoa24510-bib-0020" ref-type="bibr">20</xref>].</p><p>Additional details regarding cell phenotypes and markers can be found in the online material.</p></sec><sec id="cytoa24510-sec-0002"><label>2</label><title>SIMILARITIES TO PUBLISHED <styled-content style="fixed-case" toggle="no">OMIPs</styled-content>
</title><p>Currently, there is no OMIP tailored explicitly to the need of monitoring a regenerating immune system post&#8208;HSCT. OMIP&#8208;080 represents a unique combination allowing for comprehensive monitoring of NK cell, NKT&#8208;like cell and both &#947;&#948;T and &#945;&#946;T cell reconstitution using qualitative and functional markers. It identifies NK cell subsets similarly to OMIP 007, 039, 070 and evaluates the expression of activating and inhibitory receptors. However, OMIP&#8208;080 also includes DNAM&#8208;1, which plays roles in the regulation of relapses. Furthermore, it evaluates functional properties of NK cells such as perforin production.</p><p>T cell reconstitution is also a priority of the panel and therefore it maps the emergence of RTE defined similarly to OMIP 013 and monitors the differentiation status Th subsets similarly to OMIP 017 and 030. In contrast to OMIP 030, it defines memory subsets using CD62L and identifies cytotoxic CD4 T cells as a unique subset. Furthermore, our panel allows for deeper analysis of Treg function through evaluation of CD39 expression similarly to OMIP 004 and 015, and identification of highly suppressive populations based on expression of PD1, TIGIT, Tim3. Similarly, to OMIP 037 and 050 our panel detects markers of exhaustion, senescence and activation, but also allows to map these markers to individual Th subsets.</p></sec><sec sec-type="COI-statement" id="cytoa24510-sec-0004"><title>CONFLICT OF INTEREST</title><p>The authors have no conflict of interest to declare.</p></sec><sec id="cytoa24510-sec-0005"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Sarka Vanikova:</bold> Data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); validation (equal); visualization (equal); writing &#8211; review and editing (equal). <bold>Abhishek Koladiya:</bold> Data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); validation (equal); visualization (equal); writing &#8211; review and editing (equal). <bold>Jan Musil:</bold> Conceptualization (equal); formal analysis (equal); funding acquisition (lead); methodology (equal); project administration (equal); resources (equal); supervision (lead); visualization (equal); writing &#8211; original draft (equal); writing &#8211; review and editing (equal).</p></sec><sec id="cytoa24510-sec-0006"><sec disp-level="2" id="cytoa24510-sec-0007"><title>PEER REVIEW</title><p>The peer review history for this article is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://publons.com/publon/10.1002/cyto.a.24510" ext-link-type="uri">https://publons.com/publon/10.1002/cyto.a.24510</ext-link>.</p></sec></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cytoa24510-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Appendix S1</bold>: Supporting Information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-21-s002.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="cytoa24510-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>MIFlowCyt</bold> MIFlowCyt Item Checklist.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CYTO-101-21-s001.doc" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cytoa24510-sec-0003"><title>ACKNOWLEDGMENTS</title><p>The authors would like to thank Miroslav Kratochv&#237;l for providing constructive feedback for the unsupervised analysis of data. Special thanks go to Patrik Dvo&#345;&#225;k for instrument maintenance and calibration.</p></ack><ref-list id="cytoa24510-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="cytoa24510-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0001"><string-name name-style="western"><surname>Wall</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Devine</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vasu</surname><given-names>S</given-names></string-name>. <article-title>The who, how and why: allogeneic transplant for acute myeloid leukemia in patients older than 60&#8201;years</article-title>. <source>Blood Rev</source>. <year>2017</year>;<volume>31</volume>:<fpage>362</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28802907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.blre.2017.07.002</pub-id><pub-id pub-id-type="pmcid">PMC6205157</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0002"><string-name name-style="western"><surname>Bartenstein</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Deeg</surname><given-names>HJ</given-names></string-name>. <article-title>Hematopoietic stem cell transplantation for MDS</article-title>. <source>Hematol Oncol Clin North Am</source>. <year>2010</year>;<volume>24</volume>:<fpage>407</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">20359634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hoc.2010.02.003</pub-id><pub-id pub-id-type="pmcid">PMC2848960</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0003"><string-name name-style="western"><surname>Naik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Omer</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sasa</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Yassine</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname><given-names>CE</given-names></string-name>, et al. <article-title>Allogeneic hematopoietic stem cell transplant for relapsed and refractory non&#8208;Hodgkin lymphoma in pediatric patients</article-title>. <source>Blood Adv</source>. <year>2019</year>;<volume>3</volume>:<fpage>2689</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">31511228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/bloodadvances.2018026203</pub-id><pub-id pub-id-type="pmcid">PMC6759733</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0004"><string-name name-style="western"><surname>Palumbo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cavallo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gay</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>di Raimondo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ben Yehuda</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Petrucci</surname><given-names>MT</given-names></string-name>, et al. <article-title>Autologous transplantation and maintenance therapy in multiple myeloma</article-title>. <source>New Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>895</fpage>&#8211;<lpage>905</lpage>.<pub-id pub-id-type="pmid">25184862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1402888</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0005"><string-name name-style="western"><surname>Pai</surname><given-names>S&#8208;Y</given-names></string-name>, <string-name name-style="western"><surname>Logan</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Griffith</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Buckley</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Parrott</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Dvorak</surname><given-names>CC</given-names></string-name>, et al. <article-title>Transplantation outcomes for severe combined immunodeficiency, 2000&#8211;2009</article-title>. <source>New Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>434</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">25075835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1401177</pub-id><pub-id pub-id-type="pmcid">PMC4183064</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0006"><string-name name-style="western"><surname>Gratwohl</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brand</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Frassoni</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rocha</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Niederwieser</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Reusser</surname><given-names>P</given-names></string-name>, et al. <article-title>Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time</article-title>. <source>Bone Marrow Transplant</source>. <year>2005</year>;<volume>36</volume>:<fpage>757</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">16151426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bmt.1705140</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0007"><string-name name-style="western"><surname>Kaeuferle</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Krauss</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Blaeschke</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Willier</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Feuchtinger</surname><given-names>T</given-names></string-name>. <article-title>Strategies of adoptive T&#8208;cell transfer to treat refractory viral infections post allogeneic stem cell transplantation</article-title>. <source>J Hematol Oncol</source>. <year>2019</year>;<volume>12</volume>:<fpage>13</fpage>.<pub-id pub-id-type="pmid">30728058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-019-0701-1</pub-id><pub-id pub-id-type="pmcid">PMC6364410</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0008"><string-name name-style="western"><surname>Cichocki</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Verneris</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Cooley</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bachanova</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Brunstein</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Blazar</surname><given-names>BR</given-names></string-name>, et al. <article-title>The past, present, and future of NK cells in hematopoietic cell transplantation and adoptive transfer</article-title>. <source>Curr Top Microbiol Immunol</source>. <year>2016</year>;<volume>395</volume>:<fpage>225</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">26037048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/82_2015_445</pub-id><pub-id pub-id-type="pmcid">PMC5870762</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0009"><string-name name-style="western"><surname>Shaffer</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>KC</given-names></string-name>. <article-title>How important is NK alloreactivity and KIR in allogeneic transplantation?</article-title><source>Best Pract Res Clin Haematol</source>. <year>2016</year>;<volume>29</volume>:<fpage>351</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27890259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.beha.2016.10.010</pub-id><pub-id pub-id-type="pmcid">PMC5896016</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0010"><string-name name-style="western"><surname>Storek</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Geddes</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Huard</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Helg</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chalandon</surname><given-names>Y</given-names></string-name>, et al. <article-title>Reconstitution of the immune system after hematopoietic stem cell transplantation in humans</article-title>. <source>Semin Immunopathol</source>. <year>2008</year>;<volume>30</volume>:<fpage>425</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">18949477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00281-008-0132-5</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0011"><string-name name-style="western"><surname>Ullah</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Tey</surname><given-names>SK</given-names></string-name>. <article-title>Functional reconstitution of natural killer cells in allogeneic hematopoietic stem cell transplantation</article-title>. <source>Front Immunol</source>. <year>2016</year>;<volume>7</volume>:144.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2016.00144</pub-id><pub-id pub-id-type="pmcid">PMC4831973</pub-id><pub-id pub-id-type="pmid">27148263</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0012"><string-name name-style="western"><surname>Cooper</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Fehniger</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Ghaheri</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Ghayur</surname><given-names>T</given-names></string-name>, et al. <article-title>Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset</article-title>. <source>Blood</source>. <year>2001</year>;<volume>97</volume>:<fpage>3146</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">11342442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.v97.10.3146</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0013"><string-name name-style="western"><surname>Grzywacz</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kataria</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Verneris</surname><given-names>MR</given-names></string-name>. <article-title>CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases [4]</article-title>. <source>Leukemia</source>. <year>2007</year>;<volume>21</volume>:<fpage>356</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17251901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.leu.2404499</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0014"><string-name name-style="western"><surname>Amand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iserentant</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Poli</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sleiman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fievez</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Sanchez</surname><given-names>IP</given-names></string-name>, et al. <article-title>Human CD56dimCD16dimCells as an individualized natural killer cell subset</article-title>. <source>Front Immunol</source>. <year>2017</year>;<volume>8</volume>:<fpage>699</fpage>.<pub-id pub-id-type="pmid">28674534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.00699</pub-id><pub-id pub-id-type="pmcid">PMC5474676</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0015"><string-name name-style="western"><surname>Simonetta</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pradier</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bosshard</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Masouridi&#8208;Levrat</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chalandon</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Roosnek</surname><given-names>E</given-names></string-name>. <article-title>NK cell functional impairment after allogeneic hematopoietic stem cell transplantation is associated with reduced levels of T&#8208;bet and Eomesodermin</article-title>. <source>J Immunol</source>. <year>2015</year>;<volume>195</volume>:<fpage>4712</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">26438526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1501522</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0016"><string-name name-style="western"><surname>Hilpert</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Grosse&#8208;Hovest</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gr&#252;nebach</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Buechele</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nuebling</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Raum</surname><given-names>T</given-names></string-name>, et al. <article-title>Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D&#8208;mediated NK cell responses</article-title>. <source>J Immunol</source>. <year>2012</year>;<volume>189</volume>:<fpage>1360</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">22730533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1200796</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0017"><string-name name-style="western"><surname>Carlsten</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baumann</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Simonsson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>J&#228;dersten</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Forsblom</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Hammarstedt</surname><given-names>C</given-names></string-name>, et al. <article-title>Reduced DNAM&#8208;1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome</article-title>. <source>Leukemia</source>. <year>2010</year>;<volume>24</volume>:<fpage>1607</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">20613786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/leu.2010.149</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0018"><string-name name-style="western"><surname>Stringaris</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sekine</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Khoder</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Alsuliman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Razzaghi</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sargeant</surname><given-names>R</given-names></string-name>, et al. <article-title>Leukemia&#8208;induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia</article-title>. <source>Haematologica</source>. <year>2014</year>;<volume>99</volume>:<fpage>836</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">24488563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3324/haematol.2013.087536</pub-id><pub-id pub-id-type="pmcid">PMC4008119</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0019"><string-name name-style="western"><surname>Bosch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Storek</surname><given-names>J</given-names></string-name>. <article-title>Immune reconstitution after hematopoietic cell transplantation</article-title>. <source>Curr Opin Hematol</source>. <year>2012</year>;<volume>19</volume>:<fpage>324</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">22517587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOH.0b013e328353bc7d</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0020"><string-name name-style="western"><surname>Kratochv&#237;l</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Koladiya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vondr&#225;&#353;ek</surname><given-names>J</given-names></string-name>. <article-title>Generalized EmbedSOM on quadtree&#8208;structured self&#8208;organizing maps</article-title>. <source>F1000Res</source>. <year>2020</year>;<volume>8</volume>:<fpage>2120</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.12688/f1000research.21642.1</pub-id><pub-id pub-id-type="pmcid">PMC7255855</pub-id><pub-id pub-id-type="pmid">32518625</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0021"><string-name name-style="western"><surname>Sim&#245;es</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>di Lorenzo</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Silva&#8208;Santos</surname><given-names>B</given-names></string-name>. <article-title>Molecular determinants of target cell recognition by human &#947;&#948; T cells</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>929</fpage>.<pub-id pub-id-type="pmid">29755480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.00929</pub-id><pub-id pub-id-type="pmcid">PMC5934422</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0022"><string-name name-style="western"><surname>Pauza</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Liou</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Lahusen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lapidus</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Cairo</surname><given-names>C</given-names></string-name>, et al. <article-title>Gamma delta T cell therapy for cancer: it is good to be local</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>1305</fpage>.<pub-id pub-id-type="pmid">29937769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.01305</pub-id><pub-id pub-id-type="pmcid">PMC6003257</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0023"><string-name name-style="western"><surname>Lawand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>D&#233;chanet&#8208;Merville</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dieu&#8208;Nosjean</surname><given-names>MC</given-names></string-name>. <article-title>Key features of gamma&#8208;delta T&#8208;cell subsets in human diseases and their immunotherapeutic implications</article-title>. <source>Front Immunol</source>. <year>2017</year>;<volume>8</volume>:<fpage>761</fpage>.<pub-id pub-id-type="pmid">28713381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.00761</pub-id><pub-id pub-id-type="pmcid">PMC5491929</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0024"><string-name name-style="western"><surname>Torina</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Guggino</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>la Manna</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Sireci</surname><given-names>G</given-names></string-name>. <article-title>The janus face of NKT cell function in autoimmunity and infectious diseases</article-title>. <source>Int J Mol Sci</source>. <year>2018</year>;<volume>19</volume>(<issue>2</issue>):<fpage>440</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19020440</pub-id><pub-id pub-id-type="pmcid">PMC5855662</pub-id><pub-id pub-id-type="pmid">29389901</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0025"><string-name name-style="western"><surname>Pita&#8208;L&#243;pez</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Pera</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Solana</surname><given-names>R</given-names></string-name>. <article-title>Adaptive memory of human NK&#8208;like CD8+ T&#8208;cells to aging, and viral and tumor antigens</article-title>. <source>Front Immunol</source>. <year>2016</year>;<volume>7</volume>:<fpage>616</fpage>.<pub-id pub-id-type="pmid">28066426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2016.00616</pub-id><pub-id pub-id-type="pmcid">PMC5165258</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0026"><string-name name-style="western"><surname>Godfrey</surname><given-names>DI</given-names></string-name>, <string-name name-style="western"><surname>Koay</surname><given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>McCluskey</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gherardin</surname><given-names>NA</given-names></string-name>. <article-title>The biology and functional importance of MAIT cells</article-title>. <source>Nat Immunol</source>. <year>2019</year>;<volume>20</volume>:<fpage>1110</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">31406380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-019-0444-8</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0027"><string-name name-style="western"><surname>Seggewiss</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Einsele</surname><given-names>H</given-names></string-name>. <article-title>Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update</article-title>. <source>Blood</source>. <year>2010</year>;<volume>115</volume>:<fpage>3861</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20215642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2009-12-234096</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0028"><string-name name-style="western"><surname>Ogonek</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Juric</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Ghimire</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Varanasi</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Holler</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Greinix</surname><given-names>H</given-names></string-name>, et al. <article-title>Immune reconstitution after allogeneic hematopoietic stem cell transplantation</article-title>. <source>Front Immunol</source>. <year>2016</year>;<volume>7</volume>:<fpage>507</fpage>.<pub-id pub-id-type="pmid">27909435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2016.00507</pub-id><pub-id pub-id-type="pmcid">PMC5112259</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0029"><string-name name-style="western"><surname>Ravkov</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Slev</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Heikal</surname><given-names>N</given-names></string-name>. <article-title>Thymic output: assessment of CD4+ recent thymic emigrants and T&#8208;cell receptor excision circles in infants. Cytometry. Part B</article-title>. <source>Clin Cytom</source>. <year>2017</year>;<volume>92</volume>:<fpage>249</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.b.21341</pub-id><pub-id pub-id-type="pmid">26566232</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0030"><string-name name-style="western"><surname>Schnorfeil</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Lichtenegger</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Emmerig</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Schlueter</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Neitz</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Draenert</surname><given-names>R</given-names></string-name>, et al. <article-title>T cells are functionally not impaired in AML: increased PD&#8208;1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment</article-title>. <source>J Hematol Oncol</source>. <year>2015</year>;<volume>8</volume>:<fpage>93</fpage>.<pub-id pub-id-type="pmid">26219463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-015-0189-2</pub-id><pub-id pub-id-type="pmcid">PMC4518596</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0031"><string-name name-style="western"><surname>Kong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Claxton</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Ehmann</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Rybka</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, et al. <article-title>PD&#8208;1hiTIM&#8208;3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation</article-title>. <source>Blood Cancer J</source>. <year>2015</year>;<volume>5</volume>:<elocation-id>e330</elocation-id>.<pub-id pub-id-type="pmid">26230954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bcj.2015.58</pub-id><pub-id pub-id-type="pmcid">PMC4526784</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0032"><string-name name-style="western"><surname>Kong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schell</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Claxton</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Ehmann</surname><given-names>WC</given-names></string-name>, et al. <article-title>T&#8208;cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T&#8208;cell exhaustion and poor clinical outcome in AML patients</article-title>. <source>Clin Cancer Res</source>. <year>2016</year>;<volume>22</volume>:<fpage>3057</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">26763253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-15-2626</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0033"><string-name name-style="western"><surname>Shenghui</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yixiang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jianbo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Laixi</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Z</given-names></string-name>, et al. <article-title>Elevated frequencies of CD4<sup>+</sup> CD25<sup>+</sup> CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia</article-title>. <source>Int J Cancer</source>. <year>2011</year>;<volume>129</volume>:<fpage>1373</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">21105040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.25791</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0034"><string-name name-style="western"><surname>Bansal</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Sharawat</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Vishnubhatla</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dhawan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bakhshi</surname><given-names>S</given-names></string-name>. <article-title>Regulatory T cells in pediatric AML are associated with disease load and their serial assessment suggests role in leukemogenesis</article-title>. <source>Am J Blood Res</source>. <year>2020</year>;<volume>10</volume>:<fpage>90</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">32923088</pub-id><pub-id pub-id-type="pmcid">PMC7486484</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0035"><string-name name-style="western"><surname>Elias</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rudensky</surname><given-names>AY</given-names></string-name>. <article-title>Therapeutic use of regulatory T cells for graft&#8208;versus&#8208;host disease</article-title>. <source>Br J Haematol</source>. <year>2019</year>;<volume>187</volume>:<fpage>25</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">31418827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjh.16157</pub-id><pub-id pub-id-type="pmcid">PMC8054701</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0036"><string-name name-style="western"><surname>Duhen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Duhen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lanzavecchia</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sallusto</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>DJ</given-names></string-name>. <article-title>Functionally distinct subsets of human FOXP3 + Treg cells that phenotypically mirror effector Th cells</article-title>. <source>Blood</source>. <year>2012</year>;<volume>119</volume>:<fpage>4430</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">22438251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2011-11-392324</pub-id><pub-id pub-id-type="pmcid">PMC3362361</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0037"><string-name name-style="western"><surname>Gu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, et al. <article-title>Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions</article-title>. <source>Cell Mol Immunol</source>. <year>2017</year>;<volume>14</volume>:<fpage>521</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27374793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cmi.2016.30</pub-id><pub-id pub-id-type="pmcid">PMC5518817</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0038"><string-name name-style="western"><surname>Anderson</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Joller</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kuchroo</surname><given-names>VK</given-names></string-name>. <article-title>Lag&#8208;3, Tim&#8208;3, and TIGIT: co&#8208;inhibitory receptors with specialised functions in immune regulation</article-title>. <source>Immunity</source>. <year>2016</year>;<volume>44</volume>:<fpage>989</fpage>&#8211;<lpage>1004</lpage>.<pub-id pub-id-type="pmid">27192565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2016.05.001</pub-id><pub-id pub-id-type="pmcid">PMC4942846</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0039"><string-name name-style="western"><surname>Lim</surname><given-names>EY</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Wills</surname><given-names>MR</given-names></string-name>. <article-title>The CD4+ T cell response to human cytomegalovirus in healthy and Immunocompromised people</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2020</year>;<volume>10</volume>:<fpage>202</fpage>.<pub-id pub-id-type="pmid">32509591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2020.00202</pub-id><pub-id pub-id-type="pmcid">PMC7248300</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0040"><string-name name-style="western"><surname>van Balen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>van Bergen</surname><given-names>CAM</given-names></string-name>, <string-name name-style="western"><surname>van Luxemburg&#8208;Heijs</surname><given-names>SAP</given-names></string-name>, <string-name name-style="western"><surname>de Klerk</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>van Egmond</surname><given-names>EHM</given-names></string-name>, <string-name name-style="western"><surname>Veld</surname><given-names>SAJ</given-names></string-name>, et al. <article-title>CD4 donor lymphocyte infusion can cause conversion of chimerism without GVHD by inducing immune responses targeting minor histocompatibility antigens in HLA class II</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>3016</fpage>.<pub-id pub-id-type="pmid">30619360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.03016</pub-id><pub-id pub-id-type="pmcid">PMC6305328</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0041"><string-name name-style="western"><surname>Wu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Traficante</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Risech</surname><given-names>M</given-names></string-name>, et al. <article-title>Th17&#8208;stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2012</year>;<volume>186</volume>:<fpage>420</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">22723292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201202-0182OC</pub-id><pub-id pub-id-type="pmcid">PMC3443805</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0042"><string-name name-style="western"><surname>Marqu&#233;s</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Rial</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pellay</surname><given-names>FX</given-names></string-name>, <string-name name-style="western"><surname>van Maele</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>L&#233;ger</surname><given-names>H</given-names></string-name>, et al. <article-title>Protection against Streptococcus pneumoniae serotype 1 acute infection shows a signature of Th17&#8208; and IFN&#8208;&#947;&#8208;mediated immunity</article-title>. <source>Immunobiology</source>. <year>2012</year>;<volume>217</volume>:<fpage>420</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22204818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imbio.2011.10.012</pub-id></mixed-citation></ref><ref id="cytoa24510-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="cytoa24510-cit-0043"><string-name name-style="western"><surname>Hoving</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Kolls</surname><given-names>JK</given-names></string-name>. <article-title>New advances in understanding the host immune response to pneumocystis</article-title>. <source>Curr Opin Microbiol</source>. <year>2017</year>;<volume>40</volume>:<fpage>65</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">29136537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mib.2017.10.019</pub-id><pub-id pub-id-type="pmcid">PMC5733705</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>